Granules gets U.S. FDA nod for copy of AstraZeneca’s heartburn drug
The Hindu
Granules India receives US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules, a generic version of AstraZeneca's Nexium. The annual US market for the drug is $168M, and Granules now has 62 ANDA approvals from the US FDA. Indicated for short-term treatment of GERD and reduction of NSAID-associated gastric ulcer, it can also be used for long-term treatment of pathological hypersecretory conditions.
Drugmaker Granules India has received U.S. Food and Drug Administration approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg, a generic version of AstraZeneca Pharmaceuticals Nexium Delayed-Release Capsules.
Bioequivalent and therapeutically equivalent to reference listed drug Nexium Delayed-Release Capsules, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals LP, Esomeprazole Magnesium capsules are indicated for short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
The current annual U.S. market for Esomeprazole Magnesium Delayed-Release Capsules is around $168 Million, Granules said, citing MAT Jul 2023 IQVIA/IMS Health numbers, in a release on U.S. FDA approving its abbreviated new drug application (ANDA). The company said it now has 62 ANDA approvals from the U.S. FDA (60 final and 2 tentative approvals).
Esomeprazole Magnesium capsules are also indicated for reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults as well as for long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

GCCs keep India’s tech job market alive, even as IT services industry embarks on a hiring moratorium
Global Capability Centres, offshore subsidiaries set up by multinational corporations, mostly known by an acronym GCCs, are now the primary engine sustaining India’s tech job market, contrasting sharply with the hiring slowdown witnessed by large firms in the country.

Mobile phones are increasingly migrating to smaller chips that are more energy efficient and powerful supported by specialised Neural Processing Units (NPUs) to accelerate AI workloads directly on devices, said Anku Jain, India Managing Director for MediaTek, a Taiwanese fabless semiconductor firm that claims a 47% market share India’s smartphone chipset market.

In one more instance of a wholly owned subsidiary of a Chinese multinational company in India getting ‘Indianised’, Bharti Enterprises, a diversified business conglomerate with interests in telecom, real estate, financial services and food processing among others, and the local arm of private equity major Warburg Pincus have announced to collectively own a 49% stake in Haier India, a subsidiary of the Haier Group which is headquartered in Qingdao, Shandong, China.










